Online citations, reference lists, and bibliographies.
← Back to Search

Accelerated Decline In Apolipoprotein E-ϵ4 Homozygotes With Alzheimer's Disease

S. Craft, L. Teri, S. Edland, W. Kukull, G. Schellenberg, W. McCormick, J. Bowen, E. Larson
Published 1998 · Psychology

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Background: The apolipoprotein E-ϵ4 (APOE-ϵ4) allele is a powerful genetic risk factor for the development of Alzheimer's disease (AD). AD patients who are APOE-ϵ4 homozygotes have an earlier age at onset, increased amyloid burden, and decreased acetylcholine levels-findings that suggest differences in disease severity or rate of progression. Studies of genotype differences in rate of decline, however, have produced negative results that may be due to methodologic biases. The current study examined rate of decline in the largest sample of APOE-genotyped AD patients for whom longitudinal cognitive data have been reported. Methods: Newly diagnosed patients with probable AD (n = 201) comprised four genotype groups: ϵ2/3 (n = 14), ϵ3/3 (n = 75), ϵ3/4 (n = 82), and ϵ4/4 (n = 30). The Dementia Rating Scale (DRS) was administered at baseline and then annually for 1 to 6 years (mean, 2.5 years). For each subject, a DRS slope was calculated reflecting annual rate of decline. Rate of decline as measured by DRS slope differed according to genotype, with the effect modified by DRS score (p < 0.014). At the mean DRS score observed in our sample (DRS = 105), the ϵ4/4 group had an increased rate of decline (11.9 points per year) relative to theϵ2/3 (5.8 points per year; p < 0.003), ϵ3/3(9.3 points per year; p < 0.076), and ϵ3/4 (9.6 points per year; p < 0.055) groups. At a lower DRS score(DRS = 80), even larger differences were observed among genotypes; theϵ4/4 group had a increased rate of decline (22.2 points per year) relative to the ϵ2/3 (9.7 points per year; p < 0.0006), ϵ3/4 (15.8 points per year; p < 0.020), andϵ3/3 (18.2 points per year; p < 0.173) groups. Theϵ2/3 group had a significantly slower rate of decline than all other groups at DRS scores of 80 or 105. Conclusions: APOE-ϵ4 homozygosity is associated with a faster rate of cognitive decline, whereas the ϵ2 allele slows disease progression. These findings suggest that APOE plays a mechanistic role in the progression of AD, and is not simply related to disease onset.
This paper references
10.1192/BJP.114.512.797
The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.
G. Blessed (1968)
10.1212/WNL.34.7.939
Clinical diagnosis of Alzheimer's disease
G. Mckhann (1984)
10.1136/jnnp.49.3.229
Alzheimer's disease: a correlative study.
(1986)
10.1016/0888-7543(88)90130-9
Genotyping and sequence analysis of apolipoprotein E isoforms.
M. Emi (1988)
10.1093/NAR/16.3.1215
A simple salting out procedure for extracting DNA from human nucleated cells.
S. Miller (1988)
10.1159/000181793
Postprandial changes in cytosolic free calcium and glucose uptake in adipocytes in obesity and non-insulin-dependent diabetes mellitus.
S. Segal (1990)
10.1007/BF03323960
University of Washington Alzheimer’s Disease Patient Registry (ADPR): 1987–8
E. Larson (1990)
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
J. Hixson (1990)
Apolipoprotein E- and GFAP-RNA in hippocampus during reactive synaptogenesis and terminal proliferation
J Poirier (1991)
10.1212/WNL.42.3.631
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Paulina V. Arriagada (1992)
10.1212/WNL.43.12.2457
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
J. Morris (1993)
10.1006/BBRC.1993.1423
Apolipoprotein E : binding to soluble Alzheimer's β-amyloid
T. Wisniewski (1993)
10.1016/0306-4522(93)90456-P
Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats
J. Poirier (1993)
10.1073/PNAS.90.5.1977
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
W. Strittmatter (1993)
10.1126/SCIENCE.8346443
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
E. Corder (1993)
10.1073/PNAS.90.17.8098
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.
W. Strittmatter (1993)
Apolipoprotein E: risk factor for Alzheimer disease.
M. Tsai (1994)
10.1006/exnr.1994.1019
Hypothesis: Microtubule Instability and Paired Helical Filament Formation in the Alzheimer Disease Brain Are Related to Apolipoprotein E Genotype
W. Strittmatter (1994)
10.1002/ANA.410370509
Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late‐onset alzheimer's disease
G. Frisoni (1995)
10.1001/ARCHNEUR.1995.00540250089017
Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease.
L. M. Bierer (1995)
10.1074/JBC.270.34.19791
The Inhibitory Effect of Apolipoprotein E4 on Neurite Outgrowth Is Associated with Microtubule Depolymerization (*)
B. Nathan (1995)
10.1016/0304-3940(95)11343-6
A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein ε4 allele
H. Soininen (1995)
Apolipoprotein E polymorphism and susceptibility to Alzheimer's disease.
M. Kamboh (1995)
10.1016/0304-3940(94)11107-T
Apolipoprotein ϵ4 allele and disease progression in patients with late-onset Alzheimer's disease
H. Basun (1995)
10.1056/NEJM199511093331902
Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein.
T. Polvikoski (1995)
Apolipoprotein E €4 allele is associated with deposition of amyloid P-protein following head injury
JAR Nicoll (1995)
10.1002/ANA.410390110
Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease
T. Gómez-Isla (1996)
10.1212/WNL.47.2.444
Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease
J. Growdon (1996)
10.1001/archneur.1996.00550040085017
Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease.
G. Dal Forno (1996)
Apolipoprotein E €4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer’s disease
A Kurz (1996)
10.1002/ANA.410410510
The absence of an apolipoprotein ϵ4 allele is associated with a more aggressive form of Alzheimer's disease
Y. Stern (1997)
[Dementia rating scale].
M. Yamada (1997)



This paper is referenced by
10.1186/s13195-021-00857-w
Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer’s disease
Jaeho Kim (2021)
10.3233/JAD-201182
Modifiable, Non-Modifiable, and Clinical Factors Associated with Progression of Alzheimer's Disease.
D. Loeffler (2021)
10.1016/B978-0-12-818000-6.00007-X
Sporadic Alzheimer’s triad
Xin Zhang (2021)
10.1186/s13195-020-00712-4
APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review
Sheina Emrani (2020)
10.1002/trc2.12007
Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease
Kazushi Suzuki (2020)
10.1016/b978-0-12-813955-4.00006-4
Pharmacogenomic approaches to the treatment of sporadic Alzheimer’s disease
J. Poirier (2020)
10.1038/s41598-020-58841-7
Validation of a novel and accurate ApoE4 assay for automated chemistry analyzers
Sergio Veiga (2020)
10.3390/jcm8081236
APOE Promoter Polymorphism-219T/G is an Effect Modifier of the Influence of APOE ε4 on Alzheimer’s Disease Risk in a Multiracial Sample
K. Y. Choi (2019)
10.1159/000487938
Predictors of Rapid Cognitive Decline in Patients with Mild-to-Moderate Alzheimer Disease: A Prospective Cohort Study with 12-Month Follow-Up Performed in Memory Clinics
A. Tchalla (2018)
10.3988/jcn.2018.14.2.191
Predictors of Institutionalization in Patients with Alzheimer's Disease in South Korea
Donggyu Park (2018)
Apolipoprotein ε4 and attentional control: understanding the trajectory of cognitive ageing from mid-life
Claire L. Lancaster (2018)
10.1016/bs.ircmb.2017.07.002
New Insights Into Autophagy Dysfunction Related to Amyloid Beta Toxicity and Neuropathology in Alzheimer's Disease.
C. Ntsapi (2018)
ApoE2-Mediated Neuroprotective Mechanism Through Up-regulation of Glycolysis
X. Zhang (2018)
10.1523/JNEUROSCI.2262-17.2018
Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention
Long Wu (2018)
10.1007/978-1-4939-7674-4_9
Imaging of Brain Amyloid Load in Early Alzheimer’s Disease
T. Grimmer (2018)
10.1002/ajmg.b.32499
Genomic variants, genes, and pathways of Alzheimer's disease: An overview
A. Naj (2017)
10.1016/j.jalz.2017.01.007
Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease
Jianping Jia (2017)
10.3233/JAD-161264
The Progression of Alzheimer’s Disease: Are Fast Decliners Really Fast? A Four-Year Follow-Up
F. Barocco (2017)
10.4306/JKNPA.2016.55.1.1
Clinical Implications of Transcranial Magnetic Stimulation in Alzheimer's Dementia
D. Kang (2016)
10.3233/JAD-150089
Olfactory Dysfunction in ApoE ɛ4/4 Homozygotes with Alzheimer's Disease.
S. Oleson (2015)
10.1016/B978-0-12-410529-4.00004-8
Pharmacogenomic Approaches to the Treatment of Sporadic Alzheimer Disease using Cholinomimetic Agents
J. Poirier (2015)
10.1002/ana.24369
APOEε2 is associated with milder clinical and pathological Alzheimer disease
A. Serrano-Pozo (2015)
10.3389/fnagi.2014.00154
The potential applications of Apolipoprotein E in personalized medicine
S. Villeneuve (2014)
Markers of Prognosis in Neurodegenerative Dementia
Kajsa Stubendorff (2014)
10.1159/000362926
Risk Factors That Affect Life Expectancy in Alzheimer's Disease: A 15-Year Follow-Up
C. Wattmo (2014)
10.1016/J.JSHS.2014.04.004
Exercise training and antioxidant supplementation independently improve cognitive function in adult male and female GFAP-APOE mice
K. Chaudhari (2014)
10.1371/journal.pone.0099130
Frequency of the Apolipoprotein E ε4 Allele in a Memory Clinic Cohort in Beijing: A Naturalistic Descriptive Study
X. Wang (2014)
10.1007/s13311-014-0295-9
Genetics of Alzheimer’s Disease
R. Guerreiro (2014)
10.3109/09540261.2013.859128
Rapid cognitive decline in Alzheimer's disease: a literature review
Alessandro Sona (2013)
10.1186/alzrt210
Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies
C. Wattmo (2013)
Alcohol use as a potential moderator of risk factors for Alzheimer's disease
Julija E Stelmokas (2013)
10.1159/000354363
Neuroinflammation and β Amyloid Deposition in Alzheimer's Disease: In vivo Quantification with Molecular Imaging
C. Hommet (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar